PharmaCyte Biotech stock surges following profitable exit from Femasys investment

MSN
2025.11.25 16:13
portai
I'm PortAI, I can summarize articles.

PharmaCyte Biotech Inc. (NASDAQ:PMCB) shares surged 67.8% after successfully monetizing its stake in Femasys Inc. (NASDAQ:FEMY), boosting liquidity. The sale increased PharmaCyte's cash and marketable securities to approximately $20 million, up from $13.3 million.

Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer